Theralase Technologies Inc. V.TLT

Merck loses ground to Summit

[Longholder99]

Competition in the lung cancer arena has Summit Therapeutics Ivonescimab outperforming Keytruda in NSCLC.   Gee.....if I was the Merck Board and I was reading all this discussion about Ruvidar (since Merck is manufacturing it) and my stock price just dropped on this news.  What would I do about it?

[2b7f6fab]

Actually, Keytruda is owned by the US version of Merck.  Whereas TLD1433 is manufactured by Sigma Aldrich a division of the original Merck Group of Germany.  Two separate companies.  Even so I suspect Merck USA is watching TLT. In 1891, Georg(e) Merck established himself in the United States and set up Merck & Co. with Theodore Weicker in New York. Merck & Co. was

[CancerSlayer]

Still a ways to go for Summit, but its new drug signifies there will be a growing number of/bigger bumps in the road for Merck USA.  Keytruda will face increasingly more pressure in coming years (& hopefully we have a lot to do with that pressure), not to mention the drug goes off patent in 2028, which in itself will significantly impact sales for Merck...to the likely tune of mult